Core Viewpoint - The company is planning to expand its production and research capabilities by investing in a new research and production base in Guangzhou, which is part of its C2M supply chain strategy aimed at increasing market share and competitive advantage [4][6][7]. Group 1: Meeting Information - The first extraordinary general meeting of shareholders for 2025 will be held on May 22, 2025, at 15:30 in Guangzhou [3]. - The meeting will include both on-site and online voting options for shareholders [3][4]. - The agenda includes signing an output input supervision agreement and discussing external investments [4][7]. Group 2: Investment Details - The company has acquired a land parcel (ZSCB-E3-4) of approximately 31,585 square meters for the new research and production base, which will be adjacent to another site (ZSCB-E3-3) [5][6]. - The planned investment for the new base is 600 million RMB, focusing on various functions including office, research, production, and employee facilities [6][7]. - The investment does not constitute a related party transaction or a significant asset restructuring as defined by regulations [7].

拟6亿投建研发生产基地 润本股份于2023年10月上市，主要从事个人护理类、驱蚊类产品的研发、生产和销售，目前已形成婴童护理产 品、驱蚊产品、精油产品三大核心产品系列。 5月6日晚间，润本股份发布的公告显示，公司拟在广州市黄埔区中新广州知识城国际生物医药创新园投建新的产 研基地(投资标的名称：润本生物技术研发生产基地项目)，持续巩固公司的C2M供应链壁垒，满足未来持续增长 的产销研需求。 公告显示，上述项目投资金额为6亿元，建设内容主要包含办公区、研发区、生活区、生产制造区、园区配套工 程，用于开展个护用品、化妆品、医疗器械、医药制造行业相关产品的研发、生产制造及其配套服务。 实际上，在中新广州知识城国际生物医药创新园，润本股份已重金投入生产项目。 2024年，润本股份率先竞得位于中新广州知识城国际生物医药创新园，凤亨一路以北，凤亨二路以南，康联三路 以西ZSCB-E3-3地块，面积约3.2953万平方米的国有建设用地使用权，并于当年9月审议通过《关于签署投入产出 监管协议暨对外投资的议案》，同意公司以自有或自筹资金投资7亿元建设"润本智能智造未来工厂项目"。 在业绩持续提升之时，润本股份（603193）(6 ...